My Resume
OBJECTIVE
Poised to contribute a unique blend of PhD level academic and research experience, alongside executive success in healthcare, biotech and genetics industries. Enthusiastic professional with proven record of research on molecular genetics (Publication 1), molecular biophysics (P2, P3, P4, P7), molecular, genetic, biochemical research (P5, P6), and human genetics (P8, P9, P10, P11, P12); and successful strategy execution in two enterprises (Izmir Genetik and AKSE Genetik) growing into a final EBIDTA of $5M+.
​
AREAS OF INTEREST
Translational Research, Product Research Development, Integrative Marketing and Sales in Diagnostic Testing. Genotype - Phenotype Correlation, Variant Analysis and Clinical correlation utilizing Exome Sequence data. Molecular Genetic Analysis and Epigenetics – with a special interest in Bioinformatics and Nutrigenetics. Molecular Biology and Genetics with a special interest in bioanalytical, biophysical and computational analysis. Molecular Biophysics, Genetic Screening, Biochemistry and Behavioral Genetics. Neuroeconomics.
​
PROFESSIONAL POSITIONS
CALYX CONSULTING (www.nexusgenetix.com) – Founder
01/2020 – current
-
Established numerous national and international collaborations in reproductive biology and oncology.
​
Ä°ZMÄ°R GENETÄ°K (www.izmirgenetik.com) – General Manager
06/2016 – current
-
Grew the company from start to a licensed / certified genetics laboratory, performed 20,000+ genetic testing.
-
Established numerous national and international collaborations in reproductive biology and oncology.
-
Managed to grow the marketing team of the company to 10+ marketing agents throughout Turkey.
-
Currently manage 22+ personnel at various levels, achieving a yearly EBITDA of $5M+.
AKSE GENETÄ°K – General Manager
10/2015 – current
-
Created and implemented a novel genetic product in exome sequencing, with a special interest in nutrigenetics.
-
Prepared and received funding for 9 research projects in the fields of human molecular genetics and testing.
-
Completed 10 research projects with 4 graduate and 6 undergraduate students and published 7 manuscripts.
PHARMAPLUS GENETÄ°K – Genetics and Business Development Specialist
06/2014 – 10/2015
-
Managed launch of a medical diagnostic laboratory using Next Generation Sequencing (NGS), NextSeq 500.
-
Launched the first product of the company; Non-Invasive Prenatal Test (NIPT).
BLACKMORE PARTNERS – Equity Research Intermediate
08/2012 – 05/2014
-
Managed setting up of a genetic laboratory using Next Generation Sequencing (NGS), NextSeq 500.
ACADEMIC POSITIONS
Assistant Professor
2017-2020
Faculty of Medicine, Istanbul Altinbas University, Turkey
Post-Doctoral Associate
2015-2017
Dpt. of Biological Sciences, Middle East Technical University, Turkey.
Lecturer
2013-2015
Department of Sciences, Morton College, USA.
Chemistry Laboratory Coordinator
2006-2011
Dpt. Of Chemistry, University of Illinois at Chicago, IL
EDUCATION
M.B.A.
2014
Department of Business Administration, Wayne State College, Nebraska
Ph.D.
2011
Department of Chemistry, University of Illinois at Chicago, Illinois.
M.Sc.
2003
Department of Molecular Biology and Genetics, Bilkent University, Turkey.
B.Sc.
2001
Department of Molecular Biology and Genetics, Middle East Technical University, Turkey.
Publications
1. Sevinc A., et al. Lack of association between RNASEL Arg462Gln variant and the risk of breast cancer. Anticancer Res. 24 (2004) 2547-2549.
2. Sevinc A., and Fung L. W.-M. Mutational effects on brain spectrin tetramerization. FEBS Lett. 273 (2006) 239.
3. Kang J., Song Y., Sevinc A., Fung L. W.-M. Important residue (G46) in erythroid spectrin tetramer formation. Cell. Mol. Biol. Lett. 15 (2010) 46-54.
4. Sevinc A., Witek M., and Fung L. W.-M. Yeast two-hybrid and ITC studies of alpha and beta spectrin interaction at the tetramerization site. Cell. Mol. Biol. Lett. 16 (2011) 452-461.
5. Sevinc A., and Fung L. W.-M. Non-erythroid beta spectrin interacting proteins and their effects on spectrin tetramerization. Cell. Mol. Biol. Lett. 16 (2011) 595-606.
6. Sevinc, A., Yonar, D., Severcan, F. Investigation of neurodegenerative diseases from body fluid samples using Fourier transform infrared (FTIR) spectroscopy. Biomedical Spectroscopy and Imaging 4 (2015) 341-357.
7. Sevinc, A., et al. Possible therapeutic effects of Gamma-Tocotrienol Conjugation Therapy with Doxorubicin on Hepatocellular Carcinoma Cell Line HEPG2. Biophysical Journal 113(3) (2017) 280a.
8. Aghayeva, N., Belian, A., Yaylım, Ä°., Turan, S., and Sevinc, A. Lack of association between the occurrence of ectopic pregnancy and variations in the TGFβI and E-Cadherin genes. MOJ Proteomics & Bioinformatics 8(1) (2019) 1-5.
9. Ozer, E., Sevinc, A., Ince D., Yuzuguldu, R., and Olgun, N. BRAF V600E Mutation: A Significant Biomarker for Prediction of Disease Relapse in Pediatric Langerhans Cell Histiocytosis. Pediatric and Developmental Biology (2019) 1-7.
10. Eralp, T.N., Celik, S., and Sevinc, A. A novel genetic interplay in Marfan syndrome: a brief review of literature and presentation of a case. MOJ Proteomics & Bioinformatics 10(1) (2020).
11. Eralp, T.N. and Sevinc, A. Gamma-tocotrienol therapy and its apoptotic effects on different cancer types. Recent Advances in Molecular Biology and Biochemistry 25 (2023).
12. Eralp, T.N., Sevinc, A., and Mansuroglu, B. Combination therapy application of Abemaciclib with Doxorubicin in triple negative breast cancer cell line MDA-MB-231. Cellular and Molecular Biology 70(2) (2024) 169-177.